000			11235cam a2201117 i 4500
001			ocn951661155
003			OCoLC
005			20220517104343.0
006			m d
007			cr |||||||||||
008			200410t20162016enka ob 001 0 eng
010			_a 2019452719
040			_aDLC _beng _erda _epn _cDLC _dJSTOR _dYDXCP _dCHVBK _dVT2 _dCOO _dMERER _dWY@ _dU3W _dN$T _dAGLDB _dD6H _dLND _dOAPEN _dAUW _dSNK _dINTCL _dMHW _dBTN _dDKU _dOCLCF _dVTS _dINT _dUKMGB _dWYU _dG3B _dS8J _dS9I _dFIE _dSTF _dBRX _dM8D _dS2H _dAUD
015			_aGBB6G6202 _2bnb
016	7		_a018073494 _2Uk
019			_a1116945938
020			_a9781783742301 _q(pdf)
020			_a1783742305 _q(pdf)
020			_a9781783742318 _q(epub)
020			_a1783742313 _q(epub)
020			_a9781783742325 _q(mobi)
020			_a1783742321 _q(mobi)
020			_a1783742291
020			_a9781783742295
020			_a9781783742288
020			_a1783742283
035			_a1286691 _b(N$T)
035			_a(OCoLC)951661155 _z(OCoLC)1116945938
037			_a22573/ctt1d4g39v _bJSTOR
042			_apcc
043			_ad------
050	0	0	_aRM671.5.D44
060		4	_a2017 D-799
060		4	_aQV 736.1
072		7	_aLAW093000 _2bisacsh
072		7	_aLAW050020 _2bisacsh
072		7	_aMED078000 _2bisacsh
082	0	4	_a615.1091724 _223
049			_aMAIN
100	1		_aAzam, Mohammad Monirul, _eauthor. _931189
245	1	0	_aIntellectual property and public health in the developing world / _cMonirul Azam.
264		1	_aCambridge : _bOpen Book Publishers, _c[2016]
264		4	_a©2016
300			_a1 online resource (xxii, 322 pages) : _bcolor illustrations
336			_atext _btxt _2rdacontent
337			_acomputer _bc _2rdamedia
338			_aonline resource _bcr _2rdacarrier
347			_adata file _2rda
504			_aIncludes bibliographical references (pages 281-309) and index.
505	0		_aPreface -- List of Tables -- List of Figures -- Abbreviations -- Abstract -- 1. Setting the Scene. 1.1 Background. 1.2 The Advent of TRIPS and Pharmaceutical Patents. 1.3 The Requirements of TRIPS. 1.4 TRIPS Flexibilities and the Doha Declaration. 1.5 The Experiences of Brazil, China, India and South Africa. 1.6 The Role of the WHO. 1.7 Research Questions and Methodology. 1.8 Chapter Summary -- 2. Case Study on Bangladesh's Pharmaceutical Industry, Legislative and Institutional Framework and Pricing of Pharmaceuticals. 2.1 Introduction. 2.2 Legislative Framework: Pharmaceutical Patents and Pharmaceutical Regulation. 2.2.1 Patent Regime: Patent Law and the Patent Office. 2.2.2 Pharmaceutical Regulations: Relevant Laws and the Regulatory Body. 2.2.3 Changes Required in Patent Law and Pharmaceutical Regulation in Bangladesh. 2.3 The Pharmaceutical Industry in Bangladesh. 2.3.1 The Nature and Size of Firms. 2.3.2 Competitive Scenario. 2.3.3 Local Sales, Export and Import. 2.3.4 Production Capacity and Range. 2.3.5 Use of Technology. 2.3.6 Innovation Capacity and Research and Development. 2.3.7 Government Incentives for Supply of Raw Materials and Exports. 2.3.8 Human Resources. 2.4 (Potential) Effects of Pharmaceutical Patents on the Pricing of Drugs in Bangladesh. 2.5 Waiver for the Least Developed Countries and the Pharmaceutical Industry in Bangladesh: Opportunities and Challenges. 2.6 Which Way for Bangladesh? -- 3. The Experiences of TRIPS-compliant Patent Law Reform in Brazil, China, India and South Africa -- Lessons for Bangladesh. 3.1 Background. 3.2 The Journey Towards TRIPS and Obligations for Patent Law Reforms. 3.2.1 Patentable Subject Matter. 3.2.2 Rights and Obligations of Patentees. 3.2.3 The Term of Patent Protection. 3.2.4 Enforcement Obligations. 3.2.5 Exceptions and Limitations of Exclusive Rights. 3.2.6 Provisions on August 30 Decision (Implementation of Para. 6 of the Doha Declaration). 3.3 The Experience of Brazil. 3.4 The Experience of China. 3.5 The Experience of India. 3.6 The Experience of South Africa. 3.7 Comparative Review and Lessons for the LDCs, including Bangladesh. 3.8 Concluding Remarks -- 4. The Globalising Standard of Patent Protection in WTO Law and Policy Options for the LDCs: The Context of Bangladesh. 4.1 Introduction. 4.2 Legislative Options for Bangladesh. 4.2.1 A High Threshold and Exclusion Clause. 4.2.2 Best Mode Disclosure and Disclosure of the Source of Genetic Resources and Traditional Knowledge. 4.2.3 Narrowing the Scope of Patent Claims. 4.2.4 Exceptions to Product Patent Rights. 4.2.5 Early Working (or Bolar Exceptions), Research and Experimental Use. 4.2.6 Parallel Imports. 4.2.7 Strong Compulsory Licensing Mechanisms. 4.2.8 Prior Use Exceptions. 4.2.9 Pre-grant and Post-grant Opposition. 4.2.10 Duration of Patent Protection. 4.2.11 Do Not Adopt Overprotective Enforcement Provisions. 4.3 Government Intervention Options. 4.3.1 Drug Price Control. 4.3.2 National Competition Law. 4.3.3 Patent Prize System. 4.3.4 Limit Data Protection. 4.3.5 Patent Pool on Country-specific Diseases. 4.3.6 Avoiding Bilateral Investment Treaties or Free Trade Agreements that Erode TRIPS Flexibilities. 4.3.7 Utilisation of the Transitional Period for Pharmaceutical Patents. 4.3.8 Provision for Process Patent during the Transitional Period and Adoption of a Utility Model Law. 4.3.9 Special Investment Protection Regime, Open Drug Innovation Model and Promotion of Social Business Model in the Pharmaceutical Sector. 4.4 Conclusion -- 5. Has the TRIPS Waiver Helped the Least Developed Countries Progress Towards Innovation and Compliance? 5.1 Background: TRIPS Waivers for the LDCs and Designing a Plan of Action for Graduation and Progression Towards Innovation and Compliance. 5.2 Extending the LDC Transition Period: Is it a Measure for Making a Viable Technological Base or Simply a Waste of Time? 5.3 The Case of Bangladesh: Has the Country Gained from its LDC Status and the Transition Period? 5.4 Progress Towards Graduation and Compliance. 5.4.1 When and How Might LDCs Graduate from this Category? 5.4.2 Competitiveness of the Local (Pharmaceutical) Industry and a Plan for Graduation from the LDC Category and Progress towards TRIPS Compliance: The Context of Bangladesh. 5.5 Progress towards Graduation and Compliance: Institutional and Infrastructural Issues in Bangladesh. 5.5.1 Capacity Building in the Department of Patents, Designs and Trademarks, and Intellectual Property-related Institutional and Infrastructural Issues. 5.5.2 Capacity Building in the Directorate of Drug Administration and Public Health-related Institutional and Infrastructural Issues. 5.6 Adopting a National Development-centred Intellectual Property Policy and a National Health Strategy Integrating Long-term Innovation and Access Objectives. 5.7 Collaboration between Univeristies, Industry and Government and Public-Private Partnerships. 5.8 Limitations and Further Research. 5.9 Concluding Remarks -- Bibliography -- Appendices. Appendix 1: Status of Patents in Bangladesh (1972-2012) . Appendix 2: Relevant Provisions of the TRIPS Agreement -- Index.
520			_a"Across the world, developing countries are attempting to balance the international standards of intellectual property concerning pharmaceutical patents against the urgent need for accessible and affordable medicines. In this timely and necessary book, Monirul Azam examines the attempts of several developing countries to walk this fine line. He evaluates the experiences of Brazil, China, India, and South Africa for lessons to guide Bangladesh and developing nations everywhere. Azam's legal expertise, concern for public welfare, and compelling grasp of principal case studies make Intellectual Property and Public Health in the Developing World a definitive work. The developing world is striving to meet the requirements of the World Trade Organization's TRIPS Agreement on intellectual property. This book sets out with lucidity and insight the background of the TRIPS Agreement and its implications for pharmaceutical patents, the consequences for developing countries, and the efforts of certain representative nations to comply with international stipulations while still maintaining local industry and public health. Azam then brings the weight of this research to bear on the particular case of Bangladesh, offering a number of specific policy recommendations for the Bangladeshi government--and for governments the world over. Intellectual Property and Public Health in the Developing World is a must-read for public policy-makers, academics and students, non-governmental organizations, and readers everywhere who are interested in making sure that developing nations meet the health care needs of their people."--Publisher's website.
588			_aDecription based on online resource; title from PDF title page (Open Book Publishers website, viewed on April 10, 2020).
590			_aMaster record variable field(s) change: 050
630	0	7	_aÜbereinkommen über handelsbezogene Aspekte der Rechte an geistigem Eigentum _f1994 April 15 _2gnd _931190
650		0	_aPatent medicines _xLaw and legislation _zDeveloping countries. _931191
650		0	_aDrug accessibility _zDeveloping countries. _931192
650		0	_aPharmaceutical industry _zDeveloping countries _xCost control. _931193
650		0	_aPharmaceutical policy. _931194
650		0	_aIntellectual property _zDeveloping countries. _931195
650		0	_aIntellectual property (International law) _931196
650	1	2	_aPatents as Topic. _931197
650	1	2	_aPharmaceutical Preparations _xeconomics. _931198
650	2	2	_aDeveloping Countries.
650		7	_aIntellectual property law. _2bicssc _931199
650		7	_aLaw. _2bicssc
650		7	_aLaws of Specific jurisdictions. _2bicssc _910718
650		7	_aMedical and healthcare law. _2bicssc _931200
650		7	_aPatents law. _2bicssc _931201
650		7	_aRegulation of medicines and medical devices. _2bicssc _931202
650		7	_aSocial law. _2bicssc _931203
650		7	_aLAW _xMedical Law & Legislation. _2bisacsh _931204
650		7	_aDrug accessibility. _2fast _0(OCoLC)fst01749120 _931205
650		7	_aIntellectual property. _2fast _0(OCoLC)fst00975774
650		7	_aIntellectual property (International law) _2fast _0(OCoLC)fst00975795 _931196
650		7	_aPatent medicines _xLaw and legislation. _2fast _0(OCoLC)fst01054849 _931206
650		7	_aPharmaceutical policy. _2fast _0(OCoLC)fst01060194 _931194
651		7	_aDeveloping countries. _2fast _0(OCoLC)fst01242969
650		7	_aImmaterialgüterrecht _2gnd _931207
650		7	_aKosten _2gnd _931208
650		7	_aMedizinische Versorgung _2gnd _931209
650		7	_aPharmazeutische Industrie _2gnd _931210
651		7	_aEntwicklungsländer _2gnd _926207
655		4	_aElectronic books.
710	2		_aOpen Book Publishers, _eissuing body. _931211
776	0	8	_z9781783742295 (hbk.)
776	0	8	_z1783742291 (hbk.)
776	0	8	_z9781783742288 (pbk.)
776	0	8	_z1783742283 (pbk.)
856	4	0	_3EBSCOhost _uhttps://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=1286691
938			_aYBP Library Services _bYANK _n13077794
938			_aOAPEN Foundation _bOPEN _n646664
938			_aEBSCOhost _bEBSC _n1286691
942			_cEBK
994			_a92 _bN$T
999			_c5366 _d5366